Edition:
United States

Vanda Pharmaceuticals Inc (VNDA.OQ)

VNDA.OQ on NASDAQ Stock Exchange Global Market

16.55USD
21 May 2018
Change (% chg)

-- (--)
Prev Close
$16.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
165,523
52-wk High
$20.35
52-wk Low
$11.90

Chart for

About

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment... (more)

Overall

Beta: 0.93
Market Cap(Mil.): $880.67
Shares Outstanding(Mil.): 52.11
Dividend: --
Yield (%): --

Financials

  VNDA.OQ Industry Sector
P/E (TTM): -- 223.30 32.53
EPS (TTM): -0.11 -- --
ROI: -2.58 -8.07 12.63
ROE: -2.63 -10.87 14.50

BRIEF-Vanda Pharmaceuticals Inc Reports Qtrly EPS Of $0.06

* VANDA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 02 2018

Patent on Vanda schizophrenia drug upheld by appeals court

A federal appeals court on Friday ended a bid by West-Ward Pharmaceuticals Corp to invalidate a patent on Vanda Pharmaceutical Inc's schizophrenia drug Fanapt and bring a lower-cost generic version to market.

Apr 13 2018

BRIEF-Vanda Pharmaceuticals Wins Appeal Case On Fanapt

* U.S. FEDERAL COURT AFFIRMED U.S. COURT'S DECISION THAT WEST WARD PHARMACEUTICALS INFRINGED CO'S U.S. '610 PATENT FOR FANAPT

Apr 13 2018

BRIEF-Vanda Pharmaceuticals Gets Paragraph IV Certification Notice For Generic Version Of Hetlioz Capsule

* VANDA PHARMACEUTICALS - ON MARCH 23, GOT PARAGRAPH IV CERTIFICATION NOTICE LETTER REGARDING ANDA BY TEVA FOR GENERIC VERSION OF 20MG HETLIOZ CAPSULE

Mar 26 2018

BRIEF-Vanda Pharma Prices Public Offering Of Common Stock

* ‍SALE OF 5.5 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING AT $17.00 PER SHARE​ Source text for Eikon: Further company coverage:

Mar 15 2018

BRIEF-Vanda Pharmaceuticals Inc. Proposes Public Offering Of Common Stock

* VANDA PHARMACEUTICALS INC. PROPOSES PUBLIC OFFERING OF COMMON STOCK

Mar 14 2018

BRIEF-Vanda's Hetlioz Demonstrates Efficacy To Treat Jet Lag Disorder

* HETLIOZ® (TASIMELTEON) DEMONSTRATES EFFICACY TO TREAT JET LAG DISORDER IN AN 8 HOUR PHASE ADVANCE CLINICAL STUDY

Mar 05 2018

BRIEF-Vanda Pharmaceuticals Qtrly Net Loss Per Share $0.04

* VANDA PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 AND FULL YEAR 2017 FINANCIAL RESULTS

Feb 14 2018

Competitors

Earnings vs. Estimates